Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639791 | 1.00 | HPGD (0.68) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL2056350 | 0.80 | LMNA (0.59) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL1684557 | 0.79 | KDM4E (0.70) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL3799234 | 0.79 | HPGD (0.60) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL31324205 | 0.79 | KDM4E (0.81) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL6714833 | 0.79 | LMNA (0.56) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL22728223 | 0.78 | KDM4E (0.77) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| Water SCHEMBL11335239 | 0.77 | LMNA (0.55) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL6716459 | 0.77 | KDM4E (0.52) | HPGDKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL17505205 | 0.76 | LMNA (0.54) | HPGDKDM4EALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304550-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4504701-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | Baylor College of Medicine (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196455-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | HPGD 1037/4885KDM4E 1701/4885ALDH1A1 118/4885 |
| US-20250304550-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD1 | HPGD 1318/4885KDM4E 601/4885ALDH1A1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.